Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase EARLY_PHASE1 1Phase 1 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Neoplasm Metastasis 30Prostatic Neoplasms 18Breast Neoplasms 17Lung Neoplasms 16Glioblastoma 16Carcinoma, Non-Small-Cell Lung 15Colorectal Neoplasms 14Pancreatic Neoplasms 12Multiple Myeloma 12Glioma 12Carcinoma, Renal Cell 10Brain Neoplasms 10Squamous Cell Carcinoma of Head and Neck 9Lymphoma, Large B-Cell, Diffuse 9Lymphoma, Follicular 9Astrocytoma 9Neoplasms 8Melanoma 8Leukemia, Lymphocytic, Chronic, B-Cell 8Carcinoma, Hepatocellular 8Triple Negative Breast Neoplasms 7Ovarian Neoplasms 7Lymphoma, Non-Hodgkin 7Lymphoma, Mantle-Cell 6Lymphoma, B-Cell, Marginal Zone 6Lymphoma, B-Cell 6Gliosarcoma 6Cholangiocarcinoma 6Central Nervous System Neoplasms 6Carcinoma 6

Interventions

Doxorubicin 4ribociclib 2belinostat 2Radiotherapy 2siremadlin 1selinexor 1sargramostim 1romidepsin 1peposertib 1pembrolizumab 1liposomal doxorubicin 1ixazomib 1eribulin 1cixutumumab 1avelumab 1Trabectedin 1Specimen Handling 1Radiotherapy, Intensity-Modulated 1Magnetic Resonance Spectroscopy 1Ifosfamide 1Histamine H2 Antagonists 1Gemcitabine 1Fulvestrant 1Fluorouracil 1Famotidine 1Cyclophosphamide 1Chemotherapy, Adjuvant 1Celecoxib 1Biopsy 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Liposarcoma × Magnetic Resonance Spectroscopy × Clear all
NCT05711615 2026-05-15

Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma

National Cancer Institute (NCI)

Phase 1 Recruiting
30 enrolled
Sarcoma

Leiomyosarcoma, Liposarcoma, Sarcoma, Sarcoma, Synovial, Dermatofibrosarcoma, Histiocytoma, Malignant Fibrous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡